125 related articles for article (PubMed ID: 24135398)
21. Genomic heterogeneity in multiple myeloma.
Szalat R; Munshi NC
Curr Opin Genet Dev; 2015 Feb; 30():56-65. PubMed ID: 25982873
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray.
Yyusnita ; Norsiah ; Zakiah I; Chang KM; Purushotaman VS; Zubaidah Z; Jamal R
Malays J Pathol; 2012 Dec; 34(2):133-43. PubMed ID: 23424776
[TBL] [Abstract][Full Text] [Related]
23. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
24. Genomics in multiple myeloma: biology and clinical implications.
Chng WJ; Fonseca R
Pharmacogenomics; 2005 Sep; 6(6):563-73. PubMed ID: 16142997
[TBL] [Abstract][Full Text] [Related]
25. Genomic instability in multiple myeloma: mechanisms and therapeutic implications.
Neri P; Bahlis NJ
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S69-82. PubMed ID: 23782016
[TBL] [Abstract][Full Text] [Related]
26. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
27. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?
Tassone P; Tagliaferri P; Rossi M; Gaspari M; Terracciano R; Venuta S
Eur J Cancer; 2006 Jul; 42(11):1530-8. PubMed ID: 16820292
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
29. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
Rossi M; Amodio N; Di Martino MT; Caracciolo D; Tagliaferri P; Tassone P
Curr Drug Targets; 2013 Sep; 14(10):1144-9. PubMed ID: 23834146
[TBL] [Abstract][Full Text] [Related]
30. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma.
Chng WJ; Gualberto A; Fonseca R
Leukemia; 2006 Jan; 20(1):174-6. PubMed ID: 16239907
[No Abstract] [Full Text] [Related]
31. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
32. Genetic events in the pathogenesis of multiple myeloma.
Chng WJ; Glebov O; Bergsagel PL; Kuehl WM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):571-96. PubMed ID: 18070707
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma: new aspects of biology and treatment.
Ozaki S; Kosaka M
J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
[TBL] [Abstract][Full Text] [Related]
34. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
35. The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy.
Shires K; Van Wyk T
Crit Rev Oncol Hematol; 2018 Dec; 132():17-26. PubMed ID: 30447924
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics.
Xiong Q; Zhong Q; Zhang J; Yang M; Li C; Zheng P; Bi LJ; Ge F
J Proteome Res; 2012 Apr; 11(4):2078-90. PubMed ID: 22316494
[TBL] [Abstract][Full Text] [Related]
37. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
Dalton W; Anderson KC
Clin Cancer Res; 2006 Nov; 12(22):6603-10. PubMed ID: 17121878
[TBL] [Abstract][Full Text] [Related]
38. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.
Quintanilla-Martinez L; Kremer M; Specht K; Calzada-Wack J; Nathrath M; Schaich R; Höfler H; Fend F
Am J Pathol; 2003 May; 162(5):1449-61. PubMed ID: 12707028
[TBL] [Abstract][Full Text] [Related]
39. [Studies on molecular targets in multiple myeloma].
Ozaki S
Nihon Rinsho; 2007 Jan; 65 Suppl 1():220-5. PubMed ID: 17476745
[No Abstract] [Full Text] [Related]
40. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
